RETAVASE
LOE Approachingreteplase
BLAVIAL
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RETAVASE (reteplase) is a recombinant plasminogen activator indicated for acute myocardial infarction (AMI) to improve ventricular function and reduce mortality. It works by dissolving blood clots via fibrinolysis, enabling reperfusion of occluded coronary arteries. This biologic thrombolytic is administered as an intravenous bolus injection during acute cardiac events.
LOE Approaching
With LOE approaching and moderate competitive pressure, the RETAVASE team is likely in maintenance mode with reduced headcount and focus on defending legacy market share rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke
Started May 2026
220 enrolled
Acute Ischemic Stroke
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
Started Aug 2002
2,461 enrolled
Myocardial Infarction
Career Relevance
RETAVASE presents limited career growth opportunities given its approaching LOE and mature market status; roles are primarily defensive and focused on managing decline rather than growth. This product is best suited for professionals seeking stability in a legacy franchise rather than dynamic expansion or innovation exposure.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.